Fundacion PETHEMA

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

Study on Zanubrutinib and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients

Study on Zanubrutinib and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients

Study of Ciltacabtagene Autoleucel and Drug Combination for Treatment of High-Risk Smoldering Multiple Myeloma

Study of Ciltacabtagene Autoleucel and Drug Combination for Treatment of High-Risk Smoldering Multiple Myeloma

Study of elranatamab, mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Study of elranatamab, mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Phase II study of inotuzumab ozogamicin to prevent relapse in adult high‑risk acute lymphoblastic leukaemia patients after allogeneic stem cell transplant

Phase II study of inotuzumab ozogamicin to prevent relapse in adult high‑risk acute lymphoblastic leukaemia patients after allogeneic stem cell transplant

Study on the Safety and Effectiveness of Anitocabtagene Autoleucel and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma

Study on the Safety and Effectiveness of Anitocabtagene Autoleucel and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma

Study on Early Treatment with Teclistamab and Talquetamab for Patients with Newly Diagnosed High-Risk Multiple Myeloma

Study on Early Treatment with Teclistamab and Talquetamab for Patients with Newly Diagnosed High-Risk Multiple Myeloma

Study of belantamab mafodotin with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Study of belantamab mafodotin with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Study on the Safety of Low-Dose Cytarabine or Azacitidine with Venetoclax and Quizartinib for Acute Myeloid Leukemia in Patients Aged 60+ Ineligible for Standard Chemotherapy

Study on Iberdomide and Dexamethasone, Alone or with Drug Combination, for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Study on Iberdomide and Dexamethasone, Alone or with Drug Combination, for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Study of Elranatamab for Treating Relapsed or Refractory Multiple Myeloma in Patients Previously Treated with Three Drug Classes

Study of Elranatamab for Treating Relapsed or Refractory Multiple Myeloma in Patients Previously Treated with Three Drug Classes